CCCristiana Cannata

Cristiana Cannata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cristiana Cannata has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the usefulness of existing environmental threshold concentrations (ETCs), with a focus on pharmaceuticals in surface water: a European perspective

    by Caroline T. A. Moermond, Marlene Ågerstrand, Thomas Backhaus, Cristiana Cannata, Todd Davidson, Melvin Faber, Gemma Janer, Gerd Maack, Ad Ragas, Els Smit, et al.

    Environmental Threshold Concentrations (ETCs), such as the Predicted No Effect Concentrations (PNECs) and European Environmental Quality Standards (EQSs), represent the concentration of a chemical in an environmental compartment at or below which no adverse effects are expected. While multiple ETCs may exist for a given substance across regulatory frameworks and scientific literature, selecting the most useful value can be challenging. Even when only one ETC exists, its usefulness must be evaluated. This paper addresses this challenge by providing a systematic and stepwise framework for selecting and interpreting ETCs, with a focus on human pharmaceuticals and European regulatory frameworks. However, the ideas behind this may be applied more broadly. The proposed approach begins by defining the context of the assessment and the associated protection goals. It then requires a systematic evaluation of all available ETCs, regarding their relevance and reliability. This includes the use of the most appropriate methodology and underlying data, as well as newly published information. It also considers overall uncertainties, the need to address chronic or short-term peak exposures, and whether the ETCs have been independently reviewed. We apply the framework to metoprolol to demonstrate its usefulness in ensuring that ETCs used in environmental assessments and management decisions are robust and fit for purpose.


  • Open Access

    A framework to identify high-priority legacy active pharmaceutical ingredients for environmental risk assessment

    by Cristiana Cannata, Erika Colombo, Ashenafi Legehar, Irene Bramke, Annika Buck, Anja Coors, Melvin Faber, Gemma Janer, Samuel K Maynard, Rhys Whomsley, et al.

    Active pharmaceutical ingredients (APIs) from human medicinal products are detected in surface waters globally, but the extent of their impact remains insufficiently understood. Conducting environmental risk assessments (ERAs), including experimental studies for all pharmaceuticals, is unfeasible, particularly for legacy APIs approved before the ERA became a mandatory requirement in the European Union (EU). This challenge can be addressed by prioritizing legacy APIs for ERA, as highlighted by the European Commission’s recent proposal for revised EU pharmaceutical legislation, calling for scientific criteria to prioritize legacy APIs, using a risk-based approach. In line with this, we present a risk-based prioritization framework to identify high-priority legacy APIs for further testing and ERA. The framework, which is intended as a screening and prioritization tool and not as a substitute for regulatory-compliant ERAs, was applied to a dataset of 1,687 APIs. Environmental concentrations in surface waters were estimated using European volume sales data from 2019 to 2023. Effect concentrations were predicted using multiple approaches, including Quantitative Structure–Activity Relationship (QSAR) models and theoretical therapeutic water concentrations (TWCs). By comparing predicted values against empirical ecotoxicity data, we showed that QSAR models, which generally show acceptable statistical performance, tend to underestimate the effects of highly toxic pharmaceuticals. In contrast, TWC values were more conservative but exhibited greater variability in performance. Exposure and effect concentrations were combined into preliminary risk quotients (pRQs), which were ranked and subsequently benchmarked against a reference ranking for validation. In the final step, multiple pRQs were combined into a single risk-based ranking. This list, along with a summary of ERA data availability for the included APIs, serves as a starting point for stakeholders, such as industry and regulators, to screen legacy APIs for data gaps, guiding decisions on which substances require further ERA, possibly involving testing, and what types of studies are needed.

  • Open Access

    Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessment

    by Cristiana Cannata, Thomas Backhaus, Irene Bramke, Maria Caraman, Anna Lombardo, Rhys Whomsley, Caroline T.A. Moermond, Ad M.J. Ragas


  • Open Access

    Defining the data gap: what do we know about environmental exposure, hazards and risks of pharmaceuticals in the European aquatic environment?

    by Francis D Spilsbury, P.A. Inostroza, Patrik Svedberg, Cristiana Cannata, A.M.J. Ragas, Thomas Backhaus

    Active pharmaceutical ingredients (APIs) and their transformation products inevitably enter waterways where they might cause adverse effects to aquatic organisms. Identifying the potential risks of APIs in the environment is therefore a goal and current strategic direction of environmental management described in the EU Strategic Approach to Pharmaceuticals in the Environment and the Green Deal. This is challenged by a paucity of monitoring and ecotoxicity data to adequately describe risks. In this study we analyze measured environmental concentrations (MECs) of APIs from 5933 sites in 25 European countries as documented in the EMPODAT database or collected by the German Environment Agency for the time period between 1997 to 2020. These data were compared with empirical data on the ecotoxicity of APIs from the U.S. EPA ECOTOX database. Although 1763 uniquely identifiable APIs are registered with the European Medicines Agency (EMA) for sale in the European Economic Area (EEA), only 312 (17.7%) of these are included in publicly available monitoring data, and only 36 (1.8%) compounds have sufficient ecotoxicological data to perform an EMA-compliant ERA. Among the 27 compounds with sufficient exposure and hazard data to conduct a single substance risk assessment according to EMA guidelines, four compounds (14.8%) had a median risk quotient (RQ) > 1. Endocrine disruptors had the highest median RQ, with 7.0 and 5.6 for 17α-ethinyl-estradiol and 17β-estradiol respectively. A comparison of in-silico and empirical data for 72 APIs demonstrated the high protectiveness of the current EMA guidelines, with predicted environmental concentrations (PECs) exceeding median MECs in 98.6% of cases, with a 100-fold median increase. This study describes the data shortfalls hindering an accurate assessment of the risk posed to European waterways by APIs, and identifies 68 APIs for prioritized inclusion in monitoring programs, and 66 APIs requiring ecotoxicity testing to fill current data gaps. Highlights: 1763 medicines are EMA-approved for sale in the EEA The data gap is 1201 APIs (68%) that have no ecotoxicity or public monitoring data Only 27 APIs (1.5%) have sufficient empirical data for risk assessment. ERA using 23 years of EU monitoring data shows four compounds with a median RQ > 1 Data gap APIs prioritized for monitoring programs (68) and ecotoxicity testing (66)